Systemic Lupus Erythematosus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data

Affiliations

¹ Department of Pediatrics Division of Rheumatology University of Utah, Salt Lake City, UT, USA. Electronic address: contact@brightoncollaboration.org.
² Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, USA.
³ Italian Medicines Agency (AIFA), Rome, Italy.
⁴ Brighton Collaboration Foundation, Basel, Switzerland.
⁵ Department of Vaccines Control, National Agency of Medicines and Medical Devices, Tirana, Albania.
⁶ University of Pittsburgh Medical Center, Pittsburgh, USA.
⁷ Brighton Collaboration Foundation, Basel, Switzerland; University of Basel Children's Hospital, Basel, Switzerland.

Review

Aimee O Hersh et al. Vaccine. 2016.

. 2016 Dec 12;34(51):6572-6581.

doi: 10.1016/j.vaccine.2016.09.031. Epub 2016 Nov 2.

¹ Department of Pediatrics Division of Rheumatology University of Utah, Salt Lake City, UT, USA. Electronic address: contact@brightoncollaboration.org.
² Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, USA.
³ Italian Medicines Agency (AIFA), Rome, Italy.
⁴ Brighton Collaboration Foundation, Basel, Switzerland.
⁵ Department of Vaccines Control, National Agency of Medicines and Medical Devices, Tirana, Albania.
⁶ University of Pittsburgh Medical Center, Pittsburgh, USA.
⁷ Brighton Collaboration Foundation, Basel, Switzerland; University of Basel Children's Hospital, Basel, Switzerland.

No abstract available

Keywords: Adverse event; Case definition; Guidelines; Immunization; Systemic Lupus Erythematosus.

Publication types